The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas

As the most common and deadly of primary brain tumors, malignant gliomas have earned their place within one of the most multifaceted and heavily-funded realms of medical research. Numerous avenues of pre-clinical investigation continue to provide valuable insight, but modeling the complex evolution...

Descripción completa

Detalles Bibliográficos
Autores principales: Chambers, M. R., Bentley, R. Timothy, Crossman, David K., Foote, Jeremy B., Koehler, Jey W., Markert, James M., Omar, Nidal B., Platt, Simon R., Self, D. Mitchell, Shores, Andy, Sorjonen, Donald C., Waters, Alicia M., Yanke, Amy B., Gillespie, G. Yancey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484881/
https://www.ncbi.nlm.nih.gov/pubmed/33005623
http://dx.doi.org/10.3389/fsurg.2020.00059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484881/
https://www.ncbi.nlm.nih.gov/pubmed/33005623
http://dx.doi.org/10.3389/fsurg.2020.00059

Ejemplares similares